LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and ...

Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

AstraZeneca has claimed FDA approval for its first-in-class pan-AKT inhibitor capivasertib, getting a green light for the drug as a treatment for breast cancer, but with a more restrictive label ...

AKT inhibitor. Capivasertib (Troqap) blocks certain types of AKT protein inside cells. It is used to treat some types of breast cancer where the cancer cells have certain gene changes.

Progression-free survival in the overall trial population and subjects with PI3K/AKT pathway alterations were the trial's dual primary endpoints. Results from the trial showed that Truqap plus ...

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...